比美吉珠单抗对放射学阳性中轴型脊柱关节炎脊柱MRI炎症与结构病变的2年影响:CANDEN评分III期结果
基于BE MOBILE 2及其开放标签扩展研究,102例放射学阳性中轴型脊柱关节炎患者完成基线和第16、52、104周脊柱MRI的CANDEN评分。比美吉珠单抗治疗第16周脊柱炎症总分较基线平均下降7.3,第104周为6.6;脂肪病变总分第16周较基线增加1.6,第104周为1.8;侵蚀和新骨形成评分变化微小。
要点
- 比美吉珠单抗治疗第16周脊柱炎症CANDEN总分较基线平均下降7.3,第104周维持下降6.6。
- 脂肪病变总分第16周较基线增加1.6,第104周为1.8,基线有炎症者增加更明显。
- 侵蚀和新骨形成评分在各时间点变化微小。
核心结论
- 比美吉珠单抗治疗r-axSpA患者第16周脊柱各解剖部位炎症均下降并维持至2年,脂肪病变初期增加后变化微小,侵蚀和新骨形成变化微小。
研究设计与样本
- BE MOBILE 2及其开放标签扩展研究,纳入基线和第16、52、104周均有脊柱MRI的r-axSpA患者,采用CANDEN评分评估,所有数据为观察病例。
主要发现
- 332例BE MOBILE 2患者中102例在所有四个时间点均有可用于CANDEN评分的MRI。
- 脊柱炎症总分第16周较基线平均下降7.3,第104周下降6.6,炎症子评分至第104周呈现相似模式。
- 比美吉珠单抗随机化患者脂肪病变总分第16周较基线增加1.6,第104周增加1.8;基线无炎症者各时间点变化微小。
- 侵蚀和新骨形成总分变化微小。
临床怎么用
- CANDEN评分可用于评估r-axSpA患者脊柱MRI炎症和结构病变的动态变化。
- 治疗2年内脊柱炎症持续改善,但需关注脂肪病变的初期增加。
局限性
- 仅102例患者在所有四个时间点有可用MRI,为观察病例分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the impact of 2-year treatment with bimekizumab, a dual IL-17A and IL-17F inhibitor, on spinal MRI inflammatory and structural lesions in patients with radiographic axial spondyloarthritis (r-axSpA) in BE MOBILE 2 and its open-label extension (OLE) using Canada-Denmark (CANDEN) scoring. METHODS: Patients in BE MOBILE 2 and its OLE with spinal MRIs at baseline, Weeks 16, 52 and 104 were included. MRIs were evaluated using CANDEN scores/subscores for inflammation, fat lesions, erosions and new bone formation; mean change from baseline (CfB) is reported. All data are observed case. RESULTS: Of 332 patients in BE MOBILE 2, 102 had MRIs eligible for CANDEN scoring at all four timepoints. Mean reductions from baseline in total inflammation score were observed with bimekizumab at Week 16 (CfB: -7.3), with minimal further change at Week 104 (-6.6). Largely similar patterns were observed in inflammation subscores to Week 104, including the posterolateral inflammation subscore. In bimekizumab-randomised patients, total fat lesions score increased from baseline to Week 16 (CfB: 1.6), with minimal further change at Week 104 (1.8). These increases were reflected in patients with baseline inflammation; those without baseline inflammation had minimal change at all timepoints. Minimal changes were observed in total erosions and new bone formation scores. CONCLUSIONS: In bimekizumab-treated patients with r-axSpA, comprehensive MRI CANDEN scoring showed reductions in spinal inflammation at all anatomical locations at Week 16, sustained at two years, initial increases in fat lesions with minimal subsequent change and minimal changes in erosions and new bone formation.
引用
- Maksymowych WP, Lambert RGW, Navarro-Compán V, et al. Impact of bimekizumab on CANDEN spinal MRI inflammation & structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 results. Rheumatology (Oxford). 2026. PMID: 42834433. doi:10.1093/rheumatology/keag484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。